179 related articles for article (PubMed ID: 8679512)
21. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
22. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Blicklé JF; Andres E; Brogard JM
Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
[TBL] [Abstract][Full Text] [Related]
23. Effect of miglitol administration to non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493
[TBL] [Abstract][Full Text] [Related]
24. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
[TBL] [Abstract][Full Text] [Related]
25. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Campbell LK; Baker DE; Campbell RK
Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
[TBL] [Abstract][Full Text] [Related]
26. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine.
Samulitis BK; Goda T; Lee SM; Koldovský O
Drugs Exp Clin Res; 1987; 13(8):517-24. PubMed ID: 2962844
[TBL] [Abstract][Full Text] [Related]
28. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
29. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
30. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen KV; Li X; Sclafani A
Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Kuboyama N; Hayashi I; Yamaguchi T
Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
[No Abstract] [Full Text] [Related]
32. Gas chromatographic-mass spectrometric determination of 13C-glucose level for evaluating the effect of alpha-glucosidase inhibitor acarbose on the digestion of [U-13C] starch in rat.
Goromaru T; Matsuki K; Matsuki Y
Biol Pharm Bull; 1994 Jan; 17(1):156-9. PubMed ID: 8148808
[TBL] [Abstract][Full Text] [Related]
33. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
34. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
35. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
Santeusanio F; Compagnucci P
Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
[TBL] [Abstract][Full Text] [Related]
36. Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet.
Madar Z
Am J Clin Nutr; 1989 Jan; 49(1):106-11. PubMed ID: 2643291
[TBL] [Abstract][Full Text] [Related]
37. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
[TBL] [Abstract][Full Text] [Related]
38. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
[TBL] [Abstract][Full Text] [Related]
39. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
40. The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
DeBouno JF; Michaelis OE; Tulp OL
Gen Pharmacol; 1993 Mar; 24(2):509-15. PubMed ID: 8482529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
